PreviousNextExpandCollapseSearch

Web Page-TreatmentAgent

Treatment Phase Disease Study No. Summary Status Total
Hide details for 111In-ibritumomab tiuxetan111In-ibritumomab tiuxetan
  2
Hide details for Phase IIPhase II
  2
  Leukemia  2011-0393   Dose-Intense Yttrium-90 Ibritumumab Tiuxetan (Zevalin)-Containing Non-Myeloablative Conditioning for Allogeneic Stem Cell Transplantation in B-cell Malignancies  Open  
  Lymphoma  2011-0393   Dose-Intense Yttrium-90 Ibritumumab Tiuxetan (Zevalin)-Containing Non-Myeloablative Conditioning for Allogeneic Stem Cell Transplantation in B-cell Malignancies  Open  
Hide details for 18F-PEG6-IPQA18F-PEG6-IPQA
  1
Hide details for Phase IPhase I
  1
  Lung  2009-0832   A phase I study of 18F-PEG6-IPQA as a PET Imaging Agent for Active/Mutant EGFR Expression in Tumors  Open  
Hide details for 2-Chlorodeoxyadenosine2-Chlorodeoxyadenosine
  1
Hide details for Phase IIPhase II
  1
  Leukemia  2004-0223   PHASE II STUDY OF 2-CHLORODEOXYADENOSINE (2CDA) FOLLOWED BY RITUXIMAB IN HAIRY CELL LEUKEMIA  Open  
Hide details for 5-Azacytidine5-Azacytidine
  4
Hide details for Phase I/Phase IIPhase I/Phase II
  1
  Leukemia  2012-1047   Phase I/II Study of the Combination of Quizartinib (AC220) with 5-Azacytidine or Low-Dose Cytarabine for the Treatment of Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)  Open  
Hide details for Phase IIPhase II
  3
  Leukemia  2014-0862   An Open-label Phase II Study of Lirilumab (BMS-986015) in Combination with 5-azacytidine (vidaza) for the Treatment of Patients with Refractory/Relapsed Acute Myeloid Leukemia  Open  
  Leukemia  2014-0861   An Open-label Phase II Study of Nivolumab (BMS-936558) in Combination with 5-azacytidine (Vidaza) for the Treatment of Patients with Refractory/ Relapsed Acute Myeloid Leukemia  Open  
  Leukemia  2014-0076   Phase II Study of Sorafenib Plus 5-Azacitidine for the Initial Therapy of Patients with Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome with FLT3-ITD Mutation  Open  
Hide details for 5-Fluorouracil5-Fluorouracil
  3
Hide details for Phase IIPhase II
  1
  Head And Neck  2007-0433   PHASE II TRIAL OF INDUCTION THERAPY WITH DOCETAXEL, CISPLATIN AND FLUOROURACIL IN PREVIOUSLY UNTREATED PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA AND/OR POORLY DIFFERENTIATED CARCINOMA OF THE NASAL CAVITY AND/OR PARANASAL SINUSES   Open  
Hide details for Phase IIIPhase III
  1
  Esophagus  2011-1036   Phase III Randomized Trial of Proton Beam Therapy versus Intensity-Modulated Radiation Therapy for the treatment of esophageal cancer  Open  
Hide details for N/AN/A
  1
  Breast  2014-0185    Improving Outcomes in Triple-Negative Breast Cancer Using Molecular Triaging and Diagnostic Imaging to Guide Neoadjuvant Therapy   Open  
Hide details for 5-FU5-FU
  3
Hide details for Phase IPhase I
  2
  Advanced Cancers  2014-0495   A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity, and Pharmacokinetics of AM0010 in Patients with Advanced Solid Tumors  Open  
  Solid Tumors  2013-0346   A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients with Solid Tumors  Open  
Hide details for Phase II/Phase IIIPhase II/Phase III
  1
  Colorectum  NCCTG N1048   NCCTG N1048 (PROSPECT): A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision  Open  
PreviousNextExpandCollapseSearch